Cytometry and DNA ploidy: Clinical uses and molecular perspective in gastric and lung cancer

Journal of Cellular Physiology

Volumn 222, Issue 3, 2010, Pages 532-539

  D'Urso, Vittorio ^a,b   Collodoro, Angelo ^c   Mattioli, Eliseo ^c   Giordano, Antonio ^b,c,d   Bagella, Luigi ^a,d  

^a UNIVERSITY OF SASSARI   (Italy)

^b CROM Cancer Research Center   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROCHROME;

CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHROMATIN; DISEASE MARKER; FLOW CYTOMETRY; HUMAN; INFORMATION; LUNG CANCER; METASTASIS; METHODOLOGY; PHENOTYPE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SPUTUM CYTODIAGNOSIS; STOMACH CANCER;

CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; DNA, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; PHENOTYPE; PLOIDIES; PROGNOSIS; STOMACH NEOPLASMS;

EID: 73649149026     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21991     Document Type: Review

References (38)

1. Baak JP, Janssen E. 2004. DNA ploidy analysis in histopathology. Morphometry and DNA cytometry reproducibility conditions and clinical applications. Histopathology 44:603-614.
2. Baba H, Korenaga D, Kakeji Y, Haraguchi M, Okamura T, Maehara Y. 2002. DNA ploidy and its clinical implications in gastric cancer. Surgery 131:S63-S70.
3. Bertho AL, Santiago MA, Coutinho SG. 2000. Flow cytometry in the study of cell death.Mem Inst Oswaldo Cruz 95:429-433.
4. Choma D, Daure's JP, Quantin X, Pujol JL. 2001. Aneuploidy and prognosis of non-small-cell lung cancer: A meta-analysis of published data. Br J Cancer 85:14-22.
5. Crosby ME, Jacobberger J, GuptaD,Macklis RM, Almasan A. 2007. E2F4 regulates a stable G2 arrest response to genotoxic stress in prostate carcinoma. Oncogene 26:1897-1909.
6. Darzynkiewicz Z, Gong J, Juan G, Ardelt B, Traganos F. 1996. Cytometry of cyclin proteins. Cytometry 25:1-13.
7. Darzynkiewicz Z, Crissman H, Jacobberger JW. 2004. Cytometry of the cell cycle: Cycling through history. Cytometry A 58:21-32.
8. Emlet DR, Brown KA, Kociban DL, Pollice AA, Smith CA, Ong BB, Shackney SE. 2007. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 6:2664-2674.
9. Giaretti W. 1997. Origins of flow cytometry and applications in oncology. J Clin Pathol 50:275-277.
10. Golias CH, Charalabopoulos A, Charalabopoulos K. 2004. Cell proliferation and cell cycle control: A mini review. Int J Clin Pract 58:1134-1141.
11. Gong J, Ardelt B, Traganos F, Darzynkiewicz Z. 1994. Unscheduled expression of cyclin B1 and cyclin E in several leukemic and solid tumor cell lines. Cancer Res 54:4285-4288.
12. HaroskeG, Baak JP,DanielsenH,Giroud F, GschwendtnerA, OberholzerM, Reith A, Spieler P, Böcking A. 2001. Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Anal Cell Pathol 23:89-95.
13. Ikeda N, MacAulay C, Lam S, LeRiche J, Payne P, Garner D, Konaka C, Kato H, Palcic B. 1998. Malignancy associated changes in bronchial epithelial cells and clinical application as a biomarker. Lung Cancer 19:161-166.
14. Jacobberger JW, Frisa PS, Sramkoski RM, Stefan T, Shults KE, Soni DV. 2008. A new biomarker for mitotic cells. Cytometry A 73:5-15.
15. Juan G, Gong J, Traganos F, Darzynkiewicz Z. 1996. Unscheduled expression of cyclins D1 and D3 in human tumour cell lines. Cell Prolif 29:259-266.
16. Krutzik PO, Irish JM, Nolan GP, Perez OD. 2004. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: Techniques and clinical applications. Clin Immunol 110:206-221.
17. Lee GS, Ryu KS, Rha JG, Kim SP, Namkoong SE, Han KT. 2002. Multiparametric flow cytometric analysis in a breast cancer cell line (MCF-7). J ObstetGynaecol Res 28:141-148.
18. Leif RC, Stein JH, Zucker RM. 2004. A short history of the initial application of anti-5-BrdU to the detection and measurement of S phase. Cytometry A 58:45-52.
19. Marek W, Kotschy-Lang N, Muti A, Köhler CH, Nielsen L, Topalidis TH, Atay Z, Nakhosteen JA. 2001. Can semi-automated image cytometry on induced sputum become a screening tool for lung cancer? Evaluation of quantitative semi-automated sputum cytometry on radon- and uranium-exposed workers. Eur Respir J 18:942-950.
20. Marek W, Richartz G, Philippou S, Marek L, Kotschy-LangN. 2007. Sputum screening for lung cancer in radon exposed uranium miners: A comparison of semi-automated sputum cytometry and conventional cytology. J Physiol Pharmacol 58:349-361.
21. Nesi G, Bruno L, Saieva C, Caldini A,Girardi LR, Zanna I, Rapi S, Bechi P, Cortesini C, Palli D. 2007. DNA ploidy and S-phase fraction as prognostic factors in surgically resected gastric carcinoma: A 7-year prospective study. Anticancer Res 27:4435-4441.
22. Nunez R. 2001.DNAmeasurement and cell cycle analysis by flowcytometry. Curr Issues Mol Biol 3:67-70.
23. Palcic B, Garner DM, Beveridge J, Sun XR, Doudkine A, MacAulay C, Lam S, Payne PW. 2002. Increase of sensitivity of sputum cytology using high-resolution image cytometry: Field study results. Cytometry 50:168-176.
24. Perez OD, Mitchell D, Nolan GP. 2007. Differential role of ICAM ligands in determination of human memory T cell differentiation. BMC Immunol 8:2.
25. Pinto AE, Andre S, Soares J. 1999. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: A multivariate analysis of prognostic markers in a series of 308 patients. J Clin Pathol 52:604-611.
26. Ronzoni S, Faretta M, Ballarini M, Pelicci P, Minucci S. 2005. New method to detect histone acetylation levels by flow cytometry. Cytometry A 66:52-61.
27. Sampedro A, Salas-Bustamante A, López-Artimez M, García-Muñíz JL, Urdiales G. 1999. Cell cycle flow cytometric analysis in the diagnosis and management of colorectal carcinoma. Anal Quant Cytol Histol 21:347-352.
28. Sanad SM, Mangoud AM, Shalabi AA, Saber M, Fouad MA. 2004. DNA ploidy and S-phase fraction in the patients of chronicHCVand hepatocellular carcinomas. J Egypt Soc Parasitol 34:483-500.
29. Schmid K, Angerstein N, Geleff S, Gschwendtner A. 2006. Quantitative nuclear texture features analysis confirms WHO classification 2004 for lung carcinomas. Mod Pathol 19:453-459.
30. Schorl C, Sedivy JM. 2007. Analysis of cell cycle phases and progression in cultured mammalian cells. Methods 41:143-150.
31. Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, SharpeO, Chen J, Mitchell DJ, Chang M, Nolan GP, Steinman L, Felsher DW. 2007. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood 110:2674-2684.
32. Smolewski P, Bedner E, Du L, Hsieh TC,WuJM, Phelps DJ,Darzynkiewicz Z. 2001. Detection of caspases activation by fluorochrome-labeled inhibitors: Multiparameter analysis by laser scanning cytometry. Cytometry 44:73-82.
33. Sramkoski RM, Wormsley SW, Bolton WE, Crumpler DC, Jacobberger JW. 1999. Simultaneous detection of cyclin B1, p105, and DNA content provides complete cell cycle phase fraction analysis of cells that endoreduplicate. Cytometry 35:274-283.
34. Sugai T, Habano W, Jiao YF, Suzuki M, Takagane A, Nakamura S. 2005. Analysis of genetic alterations associated with DNA diploidy, aneuploidy and multiploidy in gastric cancers. Oncology 68:548-557.
35. Tung JW, Heydari K, Tirouvanziam R, Sahaf B, Parks DR, Herzenberg LA, Herzenberg LA. 2007. Modern flow cytometry: A practical approach. Clin Lab Med 27:453-468.
36. Xing S, Khanavkar B, Nakhosteen JA, Atay Z, Jöckel KH, Marek W. 1999. RIDTELC Lung Study Group: Predictive value of image cytometry for diagnosis of lung cancer in heavy smokers. Eur Respir J 25:956-963.
37. Yasa MH, Bektas A, Yukselen V, Akbulut H, Camci C, Ormeci N. 2005. DNA analysis and DNA ploidy in gastric cancer and gastric precancerous lesions. Int J Clin Pract 59:1029-1033.
38. Zhao H, Traganos F, Darzynkiewicz Z. 2008. Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation. Cell Cycle 7:3048-3055.